(MENAFN- Baystreet) SunCar Jumps on Latest News
Arm Holdings To Launch First A.I. Chip In 2025: Reports
GameStop Shares Rise 20% As 'Roaring Kitty' Returns
Tesla To Expand Supercharger
Network Antelope Reports Results, Shares Drop Previous Articles Subscribe to Get Small Cap News & Alerts Baystreet Staff - Monday, May 13, 2024
Johnson & Johnson To Sell Entire Stake In Spin-Off Kenvue Healthcare giant Johnson & Johnson (JNJ) plans to sell its entire stake in spun-off company Kenvue (KVUE).
Johnson & Johnson currently holds 182.3 million shares in Kenvue stock. The company plans to sell the shares it owns in a debt-for-equity exchange.
Kenvue made its market debut through an initial public offering (IPO) in May 2023.
Johnson & Johnson initially sold 172.8 million shares of the business, raising $3.8 billion U.S. in the process.
Management at Johnson & Johnson previously said that they planned to continue to own a stake of about 91% in Kenvue. Now, they appear to be reversing course with plans to sell the entire holding.
Kenvue is the company behind the consumer healthcare products that Johnson & Johnson previously made, including Listerine mouthwash, Aveeno skin care, and Tylenol.
Johnson & Johnson is now focused on making prescription medications and medical devices.
The spin-off of the consumer health business came about after Johnson & Johnson faced multiple lawsuits over allegations that its baby powder caused cancer in some people.
Earlier this year, Johnson & Johnson agreed to pay $700 million U.S. to resolve an investigation by more than 40 states into the marketing of its talcum powder.
Kenvue's stock has declined 22% since its market debut a year ago and now trades at $20.54 U.S. per share.
Johnson & Johnson's stock has declined 6% over the last 12 months and currently trades at $149.91 U.S. per share.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN13052024000212011056ID1108206472
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.